| Name | Title | Contact Details |
|---|
Biochrom is a Holliston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Marys Children's Hospital is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Taueret Laboratories is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elanco Animal Health Incorporated is a prominent American pharmaceutical company focused on developing, manufacturing, and marketing medicines and vaccinations for pets and livestock. Established in 1954 as a division of Eli Lilly and Company, Elanco became an independent entity in 2018 and has since grown to be one of the largest independent animal health companies worldwide. The acquisition of Bayer Animal Health in 2020 significantly expanded its size and global reach. Elanco offers a wide range of products aimed at enhancing animal health and productivity. This includes pharmaceuticals and vaccines for livestock and companion animals, nutritional solutions to improve feed efficiency, and data analytics through its Elanco Knowledge Solutions division. The company serves a diverse customer base, including farmers, veterinarians, pet owners, and agricultural stakeholders, all dedicated to improving animal health and food quality. Elancos mission emphasizes the importance of food and companionship in enriching life, reflecting its commitment to animal welfare and innovation in the animal health sector.
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT`s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT`s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.